After completing the $3.3bn deal package offloading its global biosimilars unit to Biocon Biologics, Viatris named four more businesses planned for the auction block under its proposed $9bn global overhaul, with a focus on setting up for ‘Phase 2’ of its strategic roadmap beginning in 2024.
With roughly two-thirds of its revenues in 2023 expected to come from branded products, the reshaped company has tapped the vast experience of former Celgene executive
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?